Climb Bio Inc (CLYM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Climb Bio Inc (CLYM) has a cash flow conversion efficiency ratio of -0.097x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.38 Million) by net assets ($148.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Climb Bio Inc to measure how much of total assets are equity-financed.
Climb Bio Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Climb Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check total reinvestment intensity of Climb Bio Inc to assess the company's total reinvestment commitment from operating cash flow.
Climb Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Climb Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Warteck Invest Ltd
SW:WARN
|
0.021x |
|
YaGuang Technology Group Co Ltd
SHE:300123
|
-0.035x |
|
Team Group Inc
TW:4967
|
-0.564x |
|
Coastal Financial Corp
NASDAQ:CCB
|
0.115x |
|
Feitian Technologies Co Ltd
SHE:300386
|
0.001x |
|
Ciputra Development Tbk
JK:CTRA
|
0.004x |
|
Sido Muncul PT
JK:SIDO
|
0.126x |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
-0.205x |
Annual Cash Flow Conversion Efficiency for Climb Bio Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Climb Bio Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see CLYM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $160.47 Million | $-54.36 Million | -0.339x | -361.18% |
| 2024-12-31 | $211.88 Million | $-15.56 Million | -0.073x | +61.63% |
| 2023-12-31 | $107.60 Million | $-20.60 Million | -0.191x | +34.06% |
| 2022-12-31 | $128.72 Million | $-37.37 Million | -0.290x | -34.57% |
| 2021-12-31 | $167.20 Million | $-36.07 Million | -0.216x | +67.00% |
| 2020-12-31 | $21.57 Million | $-14.10 Million | -0.654x | -169.03% |
| 2019-12-31 | $20.61 Million | $-5.01 Million | -0.243x | -- |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary me… Read more